Amberstone Biosciences Announces Formation of Scientific Advisory Board
Amberstone Biosciences, one of the companies invested and incubated by Viva BioInnovator, is an emerging biotech company with expertise in developing a new generation of cancer therapies. Recently, it announced the formation of a scientific advisory board which is comprised of industry leaders in the top fields of drug delivery, oncology, immunology, and pharmaceutical sciences. The advisory board will work closely with Amberstone to jointly advance the company’s therapeutic programs based on its Tumor Microenvironment Activated Therapeutics (T-MATE) platform. The members of the Amberstone board include:
- Robert Langer, ScD, a co-founder and board director of Moderna and a professor at Massachusetts Institute of Technology, also known as the “father of tissue engineering and drug discovery”
- Philip Tagari, the vice president of research at Amgen
- Other top scientists
Anji Pharma Provides Updates on Two Lead Programs
Recently, Anji Pharma, an emerging global medicines company which was invested and incubated by Viva BioInnovator, has posted updates on two lead clinical programs - ANJ908 and ANJ900. They shared the progress on these programs at two prominent scientific conferences: Digestive Disease Week (DDW) from May 21st-24th in San Diego and the American Diabetes Association (ADA) 82nd Scientific Sessions from June 3rd-7th in New Orleans. ANJ908 and ANJ900 both have major potential to unlock significant value in Anji’s clinical pipeline and fulfill the mission of improving lives globally.
-Completed patient enrollment in Phase 2 study of ANJ908 (pradigastat) in chronic idiopathic constipation.
-Currently enrolling type 2 diabetes (T2D) patients with normal, mild, and moderate chronic kidney disease (CKD stages 1-3B) in global Phase 3 study of ANJ900 (metformin delayed-release). It’s on track for Q4 2022 expansion of ANJ900 global program into T2D with CKD3B/4 in U.S., China, and rest of world.
QurAlis Announces the Appointment of Anne C. Whitaker as Chair of the Board
CAMBRIDGE, Mass., June 21, 2022—QurAlis Corporation, a biotech company that invested and incubated by Viva BioInnovator, focused on developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets, announced the appointment of Anne Clem Whitaker as chair of its board of directors.
Ms. Whitaker is a seasoned healthcare executive and director with more than 30 years of extensive leadership and commercialization experience in pharmaceuticals, biotech, consumer products, and medical devices. Her addition to the board advance the goal of halting disease progression and significantly improve outcomes for patients with ALS and other serious neurodegenerative diseases.
Copyright © Viva Biotech All Rights Reserved. 沪ICP备19036061号
- About Us
-
CRO Services
BackCRO ServicesDiscovery Biology Services
- CDMO Services
- EFS Business
- News
- Careers
- Investor Relations
- Contact Us